Vertex Pharmaceuticals Incorporated reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2015. For the quarter, the company reported total revenues of $417,935,000 compared to $144,556,000 a year ago. Loss from operations was $55,487,000 compared to $153,625,000 a year ago. Loss from continuing operations was $76,450,000 or $0.31 per basic and diluted share compared to $180,637,000 or $0.74 per basic and diluted share a year ago. Net loss attributable to the company was $75,512,000 or $0.31 per basic and diluted share compared to $176,656,000 or $0.74 per basic and diluted share a year ago. Non-GAAP net income attributable to the company was $42,657,000 or $0.17 per basic and diluted share compared to net loss of $131,832,000 or $0.55 per basic and diluted share a year ago. Non-GAAP total revenues were $410,355,000 compared to $140,588,000 a year ago.

For the year, the company reported total revenues of $1,032,336,000 compared to $580,415,000 a year ago. Loss from operations was $468,662,000 compared to $692,412,000 a year ago. Loss from continuing operations was $589,962,000 or $2.31 per basic and diluted share compared to $741,833,000 or $3.14 per basic and diluted share a year ago. Net loss attributable to the company was $558,115,000 or $2.31 per basic and diluted share compared to $738,555,000 or $3.14 per basic and diluted share a year ago. Non-GAAP net loss attributable to the company was $268,338,000 or $1.11 per basic and diluted share compared to $511,218,000 or $2.17 per basic and diluted share a year ago. Non-GAAP total revenues were $1,007,999,000 compared to $535,789,000 a year ago.

The company reiterated its 2016 net product revenue guidance for KALYDECO and guidance for non-GAAP operating expenses, excluding cost of revenues. The company also provided financial guidance for the non-GAAP R&D and SG&A components of non-GAAP operating expenses. The financial guidance is summarized below, together with information regarding the company's expectation for providing ORKAMBI net revenue guidance in 2016, as previously discussed on January 10, 2016: KALYDECO: As announced on January 10, 2016, Vertex anticipates total 2016 KALYDECO net product revenues of $670 to $690 million, which exclude any revenues related to the potential approval of KALYDECO for people in the U.S. who have residual function mutations. Anticipated 2016 KALYDECO net revenues reflect the expectation for approximately 200 patients with a gating mutation to enroll in a Phase 3 clinical study of VX-661 in combination with ivacaftor who would otherwise receive KALYDECO, which will thus reduce 2016 KALYDECO revenues. ORKAMBI: the company expects to provide net product revenue guidance for ORKAMBI during 2016 after gaining additional information on the launch of ORKAMBI in the U.S., including: The total proportion of the 8,500 eligible patients who begin treatment with ORKAMBI in 2016; The rate at which patients initiate treatment in 2016; The proportion of initiated patients who remain on treatment; The compliance rate for patients who remain on treatment.